Session Information

  • WCLC 2021

    2021 World Conference on Lung Cancer

    Conference Program for 2021 the World Conference on Lung Cancer

    Presentation Date(s):  
    • September 8 - 14, 2021
    • Total Presentations: 1107

    All times listed are in Mountain Time MDT (UTC-6:00)

    PL - Plenary
    ES - Education Session
    OA - Oral Session
    MA - Mini Oral Session
    FP - Featured Posters
    P - Posters
    WS - Workshops
    IS - Industry Symposium
    MTE - Meet the Expert
    BEDG - Brain Exchange Discussion Groups

Filter Results:

Show Only CME Accredited Sessions

  • +

    OA08 - Moving Beyond New Drugs: What Else Matters?

    • 09:30 - 10:30
    • 9/09/2021
    • Location: Program Auditorium
    • IASLC CME Accredited
    • Type: Oral
    • Track: Health Services Research/Health Economics
    • +

      OA08.01 - Trends in Within-Class Changes in US Prices of Drugs used for Metastatic Non-Small Cell Lung Cancer from 2015 to 2020

      09:30 - 09:40  |  Presenter: Aakash Desai

      • Abstract

      Loading...

    • +

      OA08.02 - First Line Treatment Patterns in Advanced NSCLC Patients With Compromised Performance Status or Comorbidities

      09:40 - 09:50  |  Presenter: Julia Judd

      • Abstract

      Loading...

    • +

      OA08.03 - The 5-year Survival Rate of Postoperative Non-small Cell Lung Cancer Patients with Two Different Follow-up Patterns

      09:50 - 10:00  |  Presenter: Daqiang Sun

      • Abstract

      Loading...

    • +

      OA08.04 - Validation of Scalable, Automated Data Extraction in an Advanced Lung Cancer Patient Population

      10:00 - 10:10  |  Presenter: Marie-pier Gauthier

      • Abstract

      Loading...

    • +

      OA08.05 - Discussant

      10:10 - 10:20  |  Presenter: Clarissa Baldotto

      • Abstract

      No abstract available for this presentation

    • +

      OA08.06 - Live Discussion with Speakers

      10:20 - 10:30

      • Abstract

      No abstract available for this presentation

  • +

    OA09 - Expanding Immunotherapy Options for Non-Small Cell Lung Cancers

    • 09:30 - 10:30
    • 9/09/2021
    • Location: Program Auditorium
    • IASLC CME Accredited
    • Type: Oral
    • Track: Immunotherapy (Phase II/III Trials)
    • +

      OA09.01 - First-line Nivolumab + Ipilimumab + Chemo in Patients With Advanced NSCLC and Brain Metastases: Results From CheckMate 9LA

      09:30 - 09:40  |  Presenter: David Carbone

      • Abstract

      Loading...

    • +

      OA09.02 - Atezo-Brain: Single Arm Phase II Study of Atezolizumab Plus Chemotherapy in Stage IV NSCLC With Untreated Brain Metastases

      09:40 - 09:50  |  Presenter: Ernest Nadal

      • Abstract

      Loading...

    • +

      OA09.03 - Pembrolizumab in Combination With Platinum-Based Chemotherapy in Recurrent EGFR/ALK-Positive Non-Small Cell Lung Cancer (NSCLC)

      09:50 - 10:00  |  Presenter: Shirish M. Gadgeel

      • Abstract

      Loading...

    • +

      OA09.04 - Discussant

      10:00 - 10:10  |  Presenter: Charu Aggarwal

      • Abstract

      No abstract available for this presentation

    • +

      OA09.05 - Live Discussion with Speakers

      10:10 - 10:30

      • Abstract

      No abstract available for this presentation

  • +

    MA07 - Liquid Biopsy Applications for Immuno-oncology, Targeted Therapies, and Early Stage NSCLC

    • 10:45 - 11:45
    • 9/09/2021
    • Location: Program Auditorium
    • IASLC CME Accredited
    • Type: Mini Oral
    • Track: Liquid Biopsy and Other Non-invasive Diagnostic Modalities
    • +

      MA07.01 - Dynamic Liquid Biopsy During Immunotherapy Anticipates Hyperprogression and Early Death in Advanced Non-Small Cell Lung Cancer

      10:45 - 10:50  |  Presenter: Laura Bonanno

      • Abstract

      Loading...

    • +

      MA07.02 - Evaluating Circulating Tumor DNA to Predict Overall Survival Risk in Non-Squamous Non-Small Cell Lung Cancer in IMpower150

      10:50 - 10:55  |  Presenter: Martin Reck

      • Abstract

      Loading...

    • +

      MA07.03 - Paired Liquid and Tissues Biopsies to Guide Treatment for Patients That Progress on 2nd Line Osimertinib Treatment

      10:55 - 11:00  |  Presenter: Tijmen van der Wel

      • Abstract

      Loading...

    • +

      MA07.04 - Discussant

      11:00 - 11:15  |  Presenter: Julia K. Rotow

      • Abstract

      No abstract available for this presentation

    • +

      MA07.05 - A Novel Blood-Based microRNA Diagnostic Test With Very High Accuracy for Early Lung Cancer Screening and Monitoring

      11:15 - 11:20  |  Presenter: Andrew Zhang

      • Abstract

      Loading...

    • +

      MA07.06 - Circulating Tumor DNA for Monitoring Minimal Residual Disease and Early Detection of Recurrence in Early Stage Lung Cancer

      11:20 - 11:25  |  Presenter: Aaron C Tan

      • Abstract

      Loading...

    • +

      MA07.07 - Detecting Stage I Lung Cancer with High Sensitivity Using Genome-wide Multi-dimensional Fragmentomic Profiles of Cell Free DNA

      11:25 - 11:30  |  Presenter: Wei Guo

      • Abstract

      Loading...

    • +

      MA07.08 - Discussant

      11:30 - 11:45  |  Presenter: Chris Abbosh

      • Abstract

      No abstract available for this presentation

  • +

    OA10 - Improving Care for People with Lung Cancer: Biomarker Testing Access, Psychosocial Distress, Care Navigation, and COVID-19 Vaccination

    • 10:45 - 11:45
    • 9/09/2021
    • Location: Program Auditorium
    • IASLC CME Accredited
    • Type: Oral
    • Track: Patient Advocacy
    • +

      OA10.01 - Perceptions of Biomarker Testing for Underserved Patients With Lung Cancer: A Mixed-Methods Survey of US-Based Oncology Clinicians

      10:45 - 10:55  |  Presenter: Leigh Boehmer

      • Abstract

      Loading...

    • +

      OA10.02 - Psychosocial Distress in Patients with Driver-Mutant Lung Cancer

      10:55 - 11:05  |  Presenter: Lia Head

      • Abstract

      Loading...

    • +

      OA10.03 - How LungMATCH, A Personalized Treatment Navigation and Clinical Trial Matching Service, Affects the Treatment Journey

      11:05 - 11:15  |  Presenter: Daniel Saez

      • Abstract

      Loading...

    • +

      OA10.04 - COVID-19 Vaccine Acceptance and Communications Effectiveness Amongst Canadian Lung Cancer Patients

      11:15 - 11:25  |  Presenter: Christina Sit

      • Abstract

      Loading...

    • +

      OA10.05 - Discussant

      11:25 - 11:35  |  Presenter: Joshua Sabari

      • Abstract

      No abstract available for this presentation

    • +

      OA10.06 - Live Discussion with Speakers

      11:35 - 11:45

      • Abstract

      No abstract available for this presentation

  • +

    OA11 - Early Stage NSCLC

    • 10:45 - 11:45
    • 9/09/2021
    • Location: Program Auditorium
    • IASLC CME Accredited
    • Type: Oral
    • Track: Early Stage/Localized Disease/Ablative Therapies
    • +

      OA11.01 - Neoadjuvant Pembrolizumab for Early Stage Non-Small Cell Lung Cancer

      10:45 - 10:55  |  Presenter: Jair Bar

      • Abstract

      Loading...

    • +

      OA11.02 - Treatment Outcomes of Re-Irradiation Using Stereotactic Ablative Radiotherapy to Lung: A Propensity Score Matching Analysis

      10:55 - 11:05  |  Presenter: Tae Hoon Lee

      • Abstract

      Loading...

    • +

      OA11.03 - Oncologic Outcomes of Patients with Resected T3N0M0 Non-Small Cell Lung Cancer

      11:05 - 11:15  |  Presenter: Edouard Marques

      • Abstract

      Loading...

    • +

      OA11.04 - Impact of Local Control on Cause-Specific Survival After SBRT for Early-Stage NSCLC: Dynamic Prediction With Landmarking

      11:15 - 11:25  |  Presenter: Kazuhito Ueki

      • Abstract

      Loading...

    • +

      OA11.05 - Discussant

      11:25 - 11:35  |  Presenter: Pamela Samson

      • Abstract

      No abstract available for this presentation

    • +

      OA11.06 - Live Discussion with Speakers

      11:35 - 11:45

      • Abstract

      No abstract available for this presentation

  • +

    MA08 - Driver Mutations and Immune Profiles in Early Stage NSCLC

    • 12:00 - 13:00
    • 9/09/2021
    • Location: Program Auditorium
    • IASLC CME Accredited
    • Type: Mini Oral
    • Track: Early Stage/Localized Disease/Ablative Therapies
    • +

      MA08.01 - Presence of High-Grade Subtype Predicts Recurrence of Stage I Lung Adenocarcinoma Only in EGFR-Mutated Patients

      12:00 - 12:05  |  Presenter: Junji Ichinose

      • Abstract

      Loading...

    • +

      MA08.02 - Outcomes of Early Stage ALK-positive NSCLC Patients in a Real-World Cohort

      12:05 - 12:10  |  Presenter: Sabine Schmid

      • Abstract

      Loading...

    • +

      MA08.03 - Adjuvant Chemotherapy for Patients with High-Risk Stage I Lung Adenocarcinoma Stratified by Epidermal Growth Factor Receptor Mutation Status

      12:10 - 12:15  |  Presenter: Yasuhiro Tsutani

      • Abstract

      Loading...

    • +

      MA08.04 - Discussant

      12:15 - 12:30  |  Presenter: Els Wauters

      • Abstract

      No abstract available for this presentation

    • +

      MA08.05 - Integrating Genomic and Transcriptomic Features Predict the Recurrence Risk of Stage IA Non-Small Cell Lung Cancer

      12:30 - 12:35  |  Presenter: Shirong Zhang

      • Abstract

      Loading...

    • +

      MA08.06 - Immune Cell Profiles as Predictors of Survival in Surgically Treated Non-Small Cell Lung Cancer (NSCLC)

      12:35 - 12:40  |  Presenter: Laura Sellmer

      • Abstract

      Loading...

    • +

      MA08.07 - Immune Characteristics Associated With Lymph Node Metastasis in Early-Stage NSCLC Discovered via T Cell Receptor Repertoires Sequencing

      12:40 - 12:45  |  Presenter: Min Li

      • Abstract

      Loading...

    • +

      MA08.08 - Discussant

      12:45 - 13:00  |  Presenter: Keiju Aokage

      • Abstract

      No abstract available for this presentation

  • +

    OA12 - Understanding and Augmenting Responses to Immunotherapy for Thoracic Malignancies

    • 12:00 - 13:00
    • 9/09/2021
    • Location: Program Auditorium
    • IASLC CME Accredited
    • Type: Oral
    • Track: Tumor Biology and Systems Biology: Basic and Translational Science
    • +

      OA12.01 - Genomic and Immune Cell Landscape of Response to Chemo-Immunotherapy in Malignant Pleural Mesothelioma

      12:00 - 12:10  |  Presenter: Valsamo Anagnostou

      • Abstract

      Loading...

    • +

      OA12.02 - Metformin Has Divergent Effects on the Tumor Immune Microenvironment of Non-Small Cell Lung Cancer (NSCLC) Depending on Obesity

      12:10 - 12:20  |  Presenter: Joseph Barbi

      • Abstract

      Loading...

    • +

      OA12.03 - Combined Inhibition of SHP2 and CXCR1/2 Promotes Anti-Tumor T Cell Response in NSCLC

      12:20 - 12:30  |  Presenter: Shuai Li

      • Abstract

      Loading...

    • +

      OA12.04 - Pre-Treatment T-Cell Receptors (TCR) Repertoire in Non-Small Cell Lung Cancer (NSCLC) Patients Treated With Single Agent Immunotherapy

      12:30 - 12:40  |  Presenter: Afaf Abed

      • Abstract

      Loading...

    • +

      OA12.05 - Discussant

      12:40 - 12:50  |  Presenter: David Carbone

      • Abstract

      No abstract available for this presentation

    • +

      OA12.06 - Live Discussion with Speakers

      12:50 - 13:00

      • Abstract

      No abstract available for this presentation

  • +

    IS05 - Industry Symposium Sponsored by Amgen: Advancing the Lung Cancer Landscape with Novel Strategies

    • 13:15 - 14:15
    • 9/09/2021
    • Location: Industry Symposium Auditorium via Industry Hub
    • Not for CME Credit
    • Type: Industry Supported Symposium
    • Track: N.A.
    • +

      IS05.01 - Welcome and Introductions

      13:15 - 13:20  |  Presenter: David R. Gandara

      • Abstract

      No abstract available for this presentation

    • +

      IS05.02 - The Evolving Biomarker Landscape in Advanced NSCLC

      13:20 - 13:35  |  Presenter: David R. Gandara

      • Abstract

      No abstract available for this presentation

    • +

      IS05.03 - KRASG12C Inhibitors – Ongoing Developments and Clinical Findings in NSCLC

      13:35 - 13:50  |  Presenter: Alexander Spira

      • Abstract

      No abstract available for this presentation

    • +

      IS05.04 - Utilizing the Potential of the BiTE® Immuno-Oncology Platform to Engage DLL3, an Emerging Target in SCLC

      13:50 - 14:05  |  Presenter: Afshin Dowlati

      • Abstract

      No abstract available for this presentation

    • +

      IS05.05 - Discussion

      14:05 - 14:15

      • Abstract

      No abstract available for this presentation

  • +

    IS06 - Industry Symposium Sponsored by Jazz Pharmaceuticals: Exploring a Treatment Option for Patients with Previously Treated Metastatic Small Cell Lung Cancer (SCLC)

    • 13:15 - 14:15
    • 9/09/2021
    • Location: Industry Symposium Auditorium via Industry Hub
    • Not for CME Credit
    • Type: Industry Supported Symposium
    • Track: N.A.
    • +

      IS06.01 - An Overview of Unmet Needs in SCLC

      13:15 - 13:30  |  Presenter: Eric Nadler

      • Abstract

      No abstract available for this presentation

    • +

      IS06.02 - Current Treatment Guidelines for SCLC

      13:30 - 13:45  |  Presenter: Eric Nadler

      • Abstract

      No abstract available for this presentation

    • +

      IS06.03 - Efficacy and Safety Findings from a Study of an FDA-Approved Treatment for Previously Treated Metastatic SCLC

      13:45 - 14:00  |  Presenter: Eric Nadler

      • Abstract

      No abstract available for this presentation

    • +

      IS06.04 - Considerations for Dosing, Administration, and Patient Counseling

      14:00 - 14:15  |  Presenter: Eric Nadler

      • Abstract

      No abstract available for this presentation

  • +

    IS07 - Satellite CME Symposium by RMEI Medical Education: On the Frontline: Immunotherapeutic Approaches in Advanced NSCLC

    • 13:15 - 14:15
    • 9/09/2021
    • Location: Program Auditorium
    • CME Accredited by Other Provider
    • Type: Satellite CME Symposia
    • Track: N.A.
    • +

      IS07.01 - Introduction

      13:15 - 13:20  |  Presenter: Roy Herbst

      • Abstract

      No abstract available for this presentation

    • +

      IS07.02 - Key Concepts in NSCLC Biomarker Testing

      13:20 - 13:35  |  Presenter: Aleš Ryška

      • Abstract

      No abstract available for this presentation

    • +

      IS07.03 - Clinical Pearls for Frontline Immunotherapy in Advanced NSCLC

      13:35 - 13:55  |  Presenter: Roy Herbst

      • Abstract

      No abstract available for this presentation

    • +

      IS07.04 - IRAE Considerations for Patients with NSCLC Receiving Immunotherapy

      13:55 - 14:05  |  Presenter: Sarah B Goldberg

      • Abstract

      No abstract available for this presentation

    • +

      IS07.05 - Live Q&A

      14:05 - 14:15

      • Abstract

      No abstract available for this presentation